Ashland (ASH) Q3 2024 earnings summary

Executive summary

• Q3 sales were $544 million, nearly flat year-over-year, with portfolio optimization reducing sales by $15 million and volume gains in Personal Care and Specialty Additives offset by Life Sciences declines.

• Net income for Q3 was $6 million, down from $50 million prior year, impacted by a $99 million impairment charge related to the planned sale of the Nutraceuticals business and non-cash charges.

• Adjusted EBITDA reached $139 million, up 5% year-over-year, driven by higher volumes, favorable mix, and deflationary raw materials, partially offset by softer pricing and higher SARD expenses.

• Personal Care delivered record sales and margin performance, while Life Sciences faced significant headwinds from VP&D, especially in Europe.

• Portfolio optimization and restructuring actions included divestiture of the nutraceuticals business, consolidation of select product lines, and accelerated depreciation and severance costs.

Financial highlights

• Sales volumes increased 5% year-over-year, led by 22% growth in Personal Care and 5% in Specialty Additives.

• Gross profit margin rose 290 basis points to 36.2%, among the highest in five years.

• Adjusted EBITDA margin improved to 25.6%, up from 24.4% last year.

• Adjusted EPS (excluding acquisition/amortization) was $1.49, up 21% year-over-year.

• Free cash flow for Q3 was $112 million, up 15% year-over-year, with 81% conversion.

Outlook and guidance

• Q4 sales expected at $530–$540 million, with adjusted EBITDA of $130–$140 million.

• Full-year sales projected at ~$2.1 billion and adjusted EBITDA at $465–$475 million.

• Portfolio optimization actions expected to reduce 2025 revenue by $160–$170 million versus 2024 and Q4 revenue by ~$20 million.

• End market demand growth forecasted as flat to low single digits; pricing expected down low single digits, partially offset by raw material deflation.

• Risks include global recession, demand recovery timing, and geopolitical uncertainties.